Publications by authors named "Daniel Sw Tan"

Claim this Profile
R
REZILIENT3: randomized phase III study of first-line zipalertinib plus chemotherapy in patients with exon 20 insertion-mutated NSCLC.
John V Heymach, Helena A Yu, Benjamin Besse, Ying Cheng, Daniel Sw Tan

Future Oncol· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Capmatinib plus nazartinib in patients with EGFR-mutated non-small cell lung cancer.
Enriqueta Felip, Giulio Metro, Ross A Soo, Jürgen Wolf, Benjamin J Solomon, Daniel Sw Tan

Eur J Cancer· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Towards proactive palliative care in oncology: developing an explainable EHR-based machine learning model for mortality risk prediction.
Qingyuan Zhuang, Alwin Yaoxian Zhang, Ryan Shea Tan Ying Cong, Grace Meijuan Yang, Patricia Soek Hui Neo, Daniel Sw Tan, Iain Beehuat Tan

BMC Palliat Care· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Genomic heterogeneity at baseline is associated with T790M resistance mutations in EGFR-mutated lung cancer treated with the first-/second-generation tyrosine kinase inhibitors.
Michael Menzel, Martina Kirchner, Klaus Kluck, Markus Ball, Susanne Beck, Daniel Sw Tan

J Pathol Clin Res· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pralsetinib in patients with RET fusion-positive non-small-cell lung cancer: A plain language summary of the ARROW study.
Frank Griesinger, Giuseppe Curigliano, Vivek Subbiah, Christina S Baik, Daniel Sw Tan

Future Oncol· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 2, multicenter, open-label study of anti-LAG-3 ieramilimab in combination with anti-PD-1 spartalizumab in patients with advanced solid malignancies.
Chia-Chi Lin, Elena Garralda, Patrick Schöffski, David S Hong, Lillian L Siu, Daniel Sw Tan, Tanay S Samant

Oncoimmunology· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Economic Evaluations of Imaging Biomarker-Driven Companion Diagnostics for Cancer: A Systematic Review.
Sibo Liu, Daniel Sw Tan, Nicholas Graves, Ann-Marie Chacko

Appl Health Econ Health Policy· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adjuvant Immunotherapy in Patients with Early-Stage Non-small Cell Lung Cancer and Future Directions.
Stephanie Pl Saw, Mei-Kim Ang, Daniel Sw Tan

Curr Treat Options Oncol· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Deficiency of the splicing factor RBM10 limits EGFR inhibitor response in EGFR-mutant lung cancer.
Shigeki Nanjo, Wei Wu, Niki Karachaliou, Collin M Blakely, Junji Suzuki, Aaron C Tan, Daniel Sw Tan

J Clin Invest· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparing the effect of a consult model versus an integrated palliative care and medical oncology co-rounding model on health care utilization in an acute hospital - an open-label stepped-wedge cluster-randomized trial.
Grace M Yang, Siqin Zhou, Zhizhen Xu, Stella Sl Goh, Xia Zhu, Daniel Sw Tan

Palliat Med· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Overcoming the impact of the COVID-19 pandemic on oncology early phase trials and drug development in Asia-Experiences and perspectives of the Asian Oncology Early Phase 1 Consortium.
Toshio Shimizu, Dong-Wan Kim, Herbert H Loong, Chia-Chi Lin, Matthew Ch Ng, Daniel Sw Tan

Asia Pac J Clin Oncol· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and efficacy of nazartinib (EGF816) in adults with EGFR-mutant non-small-cell lung carcinoma: a multicentre, open-label, phase 1 study.
Daniel S-W Tan, Natasha B Leighl, Gregory J Riely, James C-H Yang, Lecia V Sequist, Eugene Y Tan

Lancet Respir Med· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Improved Survival of Advanced Lung Cancer in Singapore Over the Past Decade.
Chee Keong Toh, Whee Sze Ong, Daniel Sw Tan, Quan Sing Ng, Ravindran Kanesvaran, Eng Huat Tan

Ann Acad Med Singap· September 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II, open-label trial to assess QTcF effects, pharmacokinetics and antitumor activity of afatinib in patients with relapsed or refractory solid tumors.
L Rhoda Molife, Sarah M Rudman, Salma Alam, Daniel S-W Tan, Hartmut Kristeleit

Cancer Chemother Pharmacol· December 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Molecular profiling for druggable genetic abnormalities in carcinoma of unknown primary.
Daniel S-W Tan, Joey Montoya, Quan-Sing Ng, Kian-Sing Chan, Oon Lynette, Eng-Huat Tan

J Clin Oncol· May 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anti-cancer drug resistance: understanding the mechanisms through the use of integrative genomics and functional RNA interference.
Daniel S-W Tan, Marco Gerlinger, Bin-Tean Teh, Charles Swanton

Eur J Cancer· August 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Truth about ERCC1 in lung cancer.
Daniel S-W Tan, Quan-Sing Ng, Iain B-H Tan, Soon-Thye Lim, Wan-Teck Lim

J Clin Oncol· April 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nucleolar localization of an isoform of the IGF-I precursor.
Daniel S-W Tan, Alexandra Cook, Shern L Chew

BMC Cell Biol· July 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis